

The Translational Research Institute for Space Health (TRISH) Joins OnPAR

FREDERICK, Md., [May 1, 2018] – Leidos welcomes the [Translational Research Institute for Space Health \(TRISH\)](#) to [OnPAR, the Online Partnership to Accelerate Research](#). OnPAR, originally launched in partnership with the National Institutes of Health, offers a new research knowledge and funding paradigm. OnPAR provides a second opportunity for promising, unfunded research proposals.

TRISH has a single overarching mission: *Lead a national effort in translating cutting-edge emerging terrestrial research into applied space flight human risk mitigation strategies for exploration missions*. TRISH seeks and funds emerging scientific and biomedical advances, radically disruptive technologies, and new engineering capabilities that can be translated for use in space.

TRISH is interested in high-risk, high-reward health research and technologies that are out-of-the-box, early-stage ideas (i.e., proof of concept) or late-stage technologies that are ready to be transitioned to operations. They will be looking for OnPAR proposals addressing the [National Aeronautics and Space Administration \(NASA\) Human Research Program](#), which is comprised of five elements: International Space Station Medical Projects, Space Radiation, Human Health Countermeasures, Exploration Medical Capability, and Human Factors and Behavioral Performance. TRISH is interested in academic, industry, defense, startups, and other projects.

Through the OnPAR public-private partnership, high-quality research applications that were not originally funded by global funding agencies are matched for potential funding within a participating organization member's specialized area of interest. In addition, OnPAR, in partnership with Digital Science, provides the global research landscape of funded applications, publications, patents, social media, and clinical trials to support and further de-risk research discovery, development, and commercialization. "We welcome TRISH to OnPAR," says Martin Dueñas, Director, Health Research Management Practice, Leidos Life Sciences. "TRISH's mission aligns with OnPAR. The TRISH program covers a broad range of challenges that OnPAR with Dimensions can support by proving a global outreach to further advance space health medicines."

"OnPAR presents a great opportunity to fund promising research proposals, advancing TRISH's mission of developing innovative approaches to reduce risks to humans on long-duration, deep-space exploration missions, including NASA's Journey to Mars," says Emmanuel Urquieta, M.D., M.S., Senior Research Portfolio Manager at the Translational Research Institute for Space Health.

Organizations interested in becoming a member can find more information on the OnPAR website at <https://onpar.leidosweb.com>. We anticipate that both new partners and members will continue to join. Please visit OnPAR frequently for further announcements and join us in our effort to accelerate research and find cures and treatments for the many diseases affecting our communities.



About TRISH

The Translational Research Institute for Space Health is part of the Center for Space Medicine at Baylor College of Medicine. TRISH is funded by a cooperative agreement from NASA to Baylor with consortium partners, the California Institute of Technology and Massachusetts Institute of Technology. Funded by NASA through a cooperative agreement, TRISH engages and enables new health technologies to predict, protect, and preserve astronaut health during deep space exploration missions. TRISH seeks high-risk, high-reward, efficient solutions that can be adapted for use in space. TRISH serves as a bridge between industry, government, and academia. TRISH engages with progressive space life scientists and organizations and provides mentorship and expertise that cannot be found elsewhere.

About Leidos

Leidos is a Fortune 500® information technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 31,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately \$10.17 billion for the fiscal year ended December 29, 2017. For more information, visit www.Leidos.com.